New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Explore this paper's citation graph
Summary
The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
- Type
- article
- Published
- 2009-01-01
- Cited by
- 26,836
- References
- 31
- OpenAlex
- https://openalex.org/W2019607817
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:8748071
Keywords
Guideline, Response Evaluation Criteria in Solid Tumors, Medicine, Clinical trial, Clinical endpoint
References
- [New guidelines to evaluate the response to treatment in solid tumors].
- Response criteria for phase II studies of supratentorial malignant glioma.
- Individual patient data analysis to assess modifications to the RECIST criteria.
- Lessons learned from independent central review.
- Imaging of the lymphatic system: new horizons.
- Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas.
- Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval
- A Simulation Study to Evaluate the Impact of the Number of Lesions Measured on Response Assessment
- Abdominal MRI advances in the detection of liver tumours and characterisation.
- Validation of Novel Imaging Methodologies for use as Cancer Clinical Trial Endpoints
- Recommendations for the assessment of progression in randomised cancer treatment trials.
- Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party.
- Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
- Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer.
- Revised response criteria for malignant lymphoma.
- New guidelines to evaluate the response to treatment in solid tumors
- Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
- Case report of a generalized seizure related to Paclitaxel infusion.
- Evaluation of lymph nodes with RECIST 1.1.
- Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Cited by
- Circulating Tumour Cells and Biomarkers in Neuroendocrine Tumours
- Bedeutung der PET für die Chirurgie des Ösophaguskarzinoms
- Onkologische Bildgebung zur Beurteilung des Therapieansprechens
- Variabilité pharmacocinétique des anti-cancéreux : Application à la vinorelbine et au lapatinib
- Kriterien für die radiologische Beurteilung des Therapieansprechens
- Evaluation of an interactive science publishing tool: toward enabling three-dimensional analysis of medical images.
- Microwave ablation of liver metastases to overcome the limitations of radiofrequency ablation
- Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document.
- Positron emission tomography and colorectal cancer.
- Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
- Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1-13C]pyruvate and [1,4-13C2]fumarate
- Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature
- Randomized phase II trials: a long-term investment with promising returns.
- Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations
- X-Ray Computed Tomography: Semiautomated Volumetric Analysis of Late-Stage Lung Tumors as a Basis for Response Assessments
- Pralatrexate with Vitamin Supplementation in Patients with Previously Treated, Advanced Non-small Cell Lung Cancer: Safety and Efficacy in a Phase 1 Trial
- Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer.
- Tumor markers in fine-needle aspiration washout for cervical lymphadenopathy in patients with known malignancy: preliminary study.
- Investigation on the use of deformable registrations in lymph node tracking over time
- Yttrium-90 Radioembolization as Salvage Therapy for Colorectal Cancer With Liver Metastases
Related papers
- Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
- Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib.
- The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms
- Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases.
- Measuring tumour response: RECIST 1.1 and beyond
- Single-Lesion Measurement per Organ for Assessing Tumor Response in Advanced Gastric Cancer
- Application of circulating tumor cells detection in chemotherapeutic efficacy evaluation of non-small cell lung cancer
- Comparison of response evaluation criteria in solid tumors (RECIST), European Association for the study of the liver (EASL) and modified RECIST criteria in evaluation of tumor response after transarteriai chemoembolization of primary liver cancer
- PUB042 Tumor Response Assessment by the Single-Lesion Measurement per Organ in Small Cell Lung Cancer
- 168P Response assessments in hepatocellular carcinoma: What are the best criteria to utilize? mRECIST or RECIST 1.1? A retrospective meta-analysis of multiple phase III trials